Wakefield, Massachusetts, November 19, 2026 / PRNewswire / -- 424, a private equity firm focusing on technology-enabled services in the healthcare and energy transition sectors for the mid-to-low end market (referred to as "424"), announced today that it has successfully exited its investment in Reverba. Reverba is a leading provider of interactive solutions for patients and medical professionals in the life sciences industry. Reverba has been acquired in a strategic transaction. The terms of the transaction were not disclosed.
In 2021, 424 collaborated with Reverba (formerly known as Health Perspectives Group), with the aim of further developing upon the company's differentiated patient interaction capabilities and creating a broader platform to provide services for pharmaceutical and biotechnology companies throughout the entire drug development and commercialization lifecycle.
424 Capital Partner Amit Nagdev stated: “Reverba embodies the kind of enterprise that 424 aims to build – one that possesses a compelling mission as well as a differentiated market positioning. We are immensely proud of the achievements made by Cheryl and the entire Reverba team during our collaboration. Together, we have strengthened the organization, expanded our capabilities, and positioned the company as a more strategic partner for some of the world’s leading life science enterprises.”
424 indicates that during its holding period, Reverba made significant investments in leadership teams, operational infrastructure, and business organizations. Reverba also expanded its capabilities by acquiring Six Degrees Medical, adding new capabilities for medical communication and interaction with medical professionals, establishing an international business presence, and moving the company's services to earlier stages of the drug development lifecycle. This integration has enabled Reverba to broaden its service scope beyond its historical focus on patient interactions, allowing the company to support both patients and medical professionals as clients in the life sciences industry.
Throughout this evolutionary process, Reverba has always focused on its core mission: to bring the patient's voice into the development and commercialization of therapies, and to help patients better understand their diseases, treatment options, and their healthcare journey. As therapies become increasingly specialized and personalized, the work of Reverba helps to make complex scientific and treatment plans more understandable and meaningful to those it serves.
Reverba CEO Cheryl Lubbert stated: "In our efforts to drive the evolution and expansion of Reverba, 424 has always been a highly supportive partner. Their team, like ours, firmly believes in the importance of our mission and has invested in talent, capabilities, and infrastructure alongside us, in order to serve clients and their patients in a more meaningful way. We are proud of everything we have built together, and we look forward to the next chapter of Reverba."
Baird serves as the exclusive financial advisor to Reverba, while Whiteman Osterman and Hannah LLP act as legal advisors.
Regarding 424 Capital
424 Capital is a private equity firm targeting the mid-to-low-end market. By collaborating with its founders and management team, it aims to accelerate the growth of technology-enabled services for enterprises. 424 adopts a highly operational investment approach, working alongside the management team to promote organizational specialization, accelerate internal growth, execute strategic acquisitions, and build a market leader with scale. For more information, please visit: www.424capital.com.
About Reverba
Reverba is a global health engagement company that helps life science organizations connect with patients and healthcare professionals through meaningful, insight-driven interactions. The company collaborates with pharmaceutical and biotechnology organizations throughout the entire therapy lifecycle, helping to bring the voices and experiences of patients and healthcare professionals into the development and commercialization of therapies.
Contact Person
Jennifer Mosto
[ email protected ]










